Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
2026-02-22 13:23:29 ET
On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome (NASDAQ:IMNM) , an estimated $12.20 million trade based on quarterly average pricing.
According to a February 17, 2026, SEC filing , Redmile Group increased its position in Immunome (NASDAQ:IMNM) by 695,000 shares during the fourth quarter of 2025. The estimated transaction value, calculated using the quarter’s average closing price, was approximately $12.20 million. The total position value at quarter-end grew by $64.01 million, a figure that includes both the new shares and changes in Immunome’s stock price.
Immunome is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapies for oncology and infectious diseases. The company’s competitive advantage lies in its differentiated pipeline and expertise in antibody engineering for complex disease targets.
NASDAQ: IMNM
IMNM Trading
-4.64% G/L:
$20.551 Last:
827,127 Volume:
$20.18 Open:
